Can CAR-T cells free HIV patients from daily medication?

NCT ID NCT04648046

Recruiting now Disease control Sponsor: Steven Deeks Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether specially engineered immune cells (CAR-T cells) can control HIV in people who stop their regular antiretroviral drugs. 18 participants will receive a single infusion of their own modified cells, with some also getting a mild chemotherapy drug beforehand. After infusion, HIV medications are paused to see if the engineered cells can keep the virus in check. The main goals are safety and whether the virus stays suppressed for at least 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genetically modified immune cells (CAR-T cells) targeting HIV
What this could lead to: If successful, this could allow people with HIV to stop daily antiretroviral therapy while keeping the virus under control.
What could go wrong: This is a very early, small trial (18 people) focused on safety. The CAR-T cells may not persist or control HIV, and there are risks from the conditioning chemotherapy and potential side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

University of California, Davis
RECRUITING

Sacramento, California, 95817, United States
Zuckerberg San Francisco General
RECRUITING

San Francisco, California, 94110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.